Treating arrhythmias: an expert opinion

Bibliography

• Wyse DG, Waldo AL, DiMarco JP, A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA, A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S, Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77
   PubMed Web of Science ®Google Scholar
• Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation. A systematic review of randomized controlled trials. Arch Intern Med 2006;166:719-28
   PubMed Web of Science ®Google Scholar
• Corley SD, Epstein AE, DiMarco JP, Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-13
   PubMed Web of Science ®Google Scholar
• Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010;375:1212-23
   PubMed Web of Science ®Google Scholar
• Echt DS, Liebson PR, Mitchell LB, Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS, ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2006;27:1979-2030
   PubMed Web of Science ®Google Scholar
• Garcia D, Cheng-Lai A. Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation. Cardiol Rev 2009;17:230-4
   PubMed Web of Science ®Google Scholar
• Camm AJ, Savelieva I. New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant. J Interv Card Electrophysiol 2008;23:7-14
   PubMed Web of Science ®Google Scholar
• Patel C, Yan GX, Kowey PR. Dronedarone. Circulation 2009;120:636-44
   PubMed Web of Science ®Google Scholar
• Touboul P, Brugada J, Capucci A, Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003;24:1481-7
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly SJ, Crijns HJ, Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-99
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M, Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
   PubMed Web of Science ®Google Scholar
• Davy JM, Herold M, Hoglund C, Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527.e1-9
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, De Ferrari GM, Radzik D, A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010;21:597-605
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crijns HJ, Torp-Pedersen C, Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009;120:1174-80
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ, Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M, Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J 2010;31:1717-21
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm [Last accessed 10 Feb 2011]
   Google Scholar
• Camm AJ, Kirchhof P, Lip GY, Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt CM, Torp-Pedersen C, Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-25
   PubMed Web of Science ®Google Scholar
• Pratt CM, Roy D, Torp-Pedersen C, Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010;106:1277-83
   PubMed Web of Science ®Google Scholar
• Kowey PR, Dorian P, Mitchell LB, Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:652-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.cardiologytoday.com/view.aspx?rid=64356 [Accessed 3 October 2010]
   Google Scholar
• Arya A, Silberbauer J, Teichman SL, A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace 2009;11:458-64
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Antzelevitch C. Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol 2008;52:121-8
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Hod H, Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-52
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Sicouri S, Di Diego JM, Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010;56:1216-24
   PubMed Web of Science ®Google Scholar
• Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006;118:321-33
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Lopes RD, Alexander JH, Al-Khatib SM, Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-9
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, O'Donnell M, Yusuf S, Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010;159:348-353.e1
   PubMed Web of Science ®Google Scholar
• ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-7.e1
   PubMed Web of Science ®Google Scholar
• Available from: http://www.medscape.com/viewarticle/732524 [Accessed 30 December 2010]
   Google Scholar
• Available from: http://www.medscape.com/viewarticle/727776 [Accessed 22 December 2010]
   Google Scholar
• Poole JE, Johnson GW, Hellkamp AS, Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-17
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Dorian P, Roberts RS, Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006;295:165-71
   PubMed Web of Science ®Google Scholar
• Ferreira-Gonzalez I, Dos-Subira L, Guyatt GH. Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. Eur Heart J 2007;28:469-77
   PubMed Web of Science ®Google Scholar
• Dorian P, Borggrefe M, Al-Khalidi HR, Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004;110:3646-54
   PubMed Web of Science ®Google Scholar
• Singer I, Al-Khalidi H, Niazi I, Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2004;43:39-43
   PubMed Web of Science ®Google Scholar
• Dorian P, Al-Khalidi HR, Hohnloser SH, Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. J Am Coll Cardiol 2008;52:1076-83
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Dorian P, Roberts R, Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006;114:104-9
   PubMed Web of Science ®Google Scholar